Q
Quantum BioPharma Ltd
CNSX:QNTM
Quantum BioPharma Ltd
CNSX:QNTM
Price:
4.12
CAD
-11.4%
Market Cap:
CA$15.8m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Q
|
Quantum BioPharma Ltd
CNSX:QNTM
|
CA |
|
Musashi Co Ltd
TSE:7521
|
JP |
|
C
|
Coca-Cola Femsa SAB de CV
F:CFSL
|
MX |
|
Il Sole 24 Ore SpA
F:4IL1
|
IT |
|
L
|
Lingkaran Trans Kota Holdings Bhd
KLSE:LITRAK
|
MY |
|
Aarvee Denims and Exports Ltd
NSE:AARVEEDEN
|
IN |
|
PKSHA Technology Inc
TSE:3993
|
JP |
|
Zhejiang Garden Bio-chemical High-tech Co Ltd
SZSE:300401
|
CN |
|
B Communications Ltd
OTC:BCOMF
|
IL |
|
National Company for Glass Industries SJSC
SAU:2150
|
SA |
|
Commonwealth Bank of Australia
ASX:CBA
|
AU |
|
C
|
CytoTools AG
XETRA:T5O
|
DE |
|
Fujian SBS Zipper Science and Technology Co Ltd
SZSE:002098
|
CN |
|
L
|
Lepu Scientech Medical Technology Shanghai Co Ltd
HKEX:2291
|
CN |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of QNTM.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
QNTM
Multiples-Based Value
Not Available
Multiples Across Competitors
QNTM Competitors Multiples
Quantum BioPharma Ltd Competitors
Quantum BioPharma Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
Q
|
Quantum BioPharma Ltd
CNSX:QNTM
|
16m CAD | 0 | -0.4 | -0.6 | -0.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
871.6B USD | 13.1 | 41.4 | 27.9 | 29.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.1B USD | 6.1 | 21.3 | 14.8 | 18.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
229B GBP | 5.2 | 29.7 | 16.4 | 23.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296.9B USD | 4.5 | 16 | 10 | 12.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
230.8B CHF | 5.1 | 20.5 | 12.7 | 16.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 11 | 8.1 | 9.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.1B USD | 2.5 | 19.9 | 7.7 | 10.2 | |
| UK |
|
GSK plc
XETRA:GS71
|
102.5B EUR | 2.7 | 15.2 | 8.2 | 10.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
